Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis

IF 2.3 4区医学 Q2 PERIPHERAL VASCULAR DISEASE

Blood Pressure Pub Date : 2017-05-04 DOI:10.1080/08037051.2016.1208730

W. Yuan, Genyang Cheng, Bin Li, Yansheng Li, Shan Lu, Dong Liu, Jing Xiao, Zhanzheng Zhao

{"title":"Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis","authors":"W. Yuan, Genyang Cheng, Bin Li, Yansheng Li, Shan Lu, Dong Liu, Jing Xiao, Zhanzheng Zhao","doi":"10.1080/08037051.2016.1208730","DOIUrl":null,"url":null,"abstract":"Abstract The aim of this meta-analysis was to assess the effectiveness and safety of endothelin-receptor antagonist (ERA) in the patients with hypertension. Searches of the PubMed, EMBASE, and CENTRAL databases were conducted to include all the randomized control trials (RCTs). Eighteen trials including 4898 patients were used in the meta-analysis, of which nine were classified as low risk of bias and the other nine as unclear risk of bias. There was no statistically significant difference in all-cause mortality between ERA and placebo groups [6 trials, fixed effects model, RR 1.53 (0.89–2.62); random effects model, RR 1.45 (0.84–2.52)]. ERA significantly reduced 24-h ambulatory blood pressure and sitting blood pressure in patients with hypertension [5 trials, 24-h SBP: WMD −7.65 (−8.95 to −6.36), 24-h DBP: WMD −5.92 (−7.50 to −4.33); 18 trials, SBP: WMD −6.12 (−7.87 to −4.36), DBP: WMD −3.81 (−4.82 to −2.80)]. However, ERA had more adverse events [within 24 h: 3 trials, RR 1.16 (0.82–1.65); after 24 h, 13 trials, RR 1.21 (1.08–1.36)] and severe adverse events than placebo controls [SAE: 9 trials, RR 1.34 (1.13–1.60)]. In addition, there is a potential need for further RCTs that focus on the use of ERA in patients with hypertension.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2017-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1208730","citationCount":"19","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Pressure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08037051.2016.1208730","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 19

Abstract

Abstract The aim of this meta-analysis was to assess the effectiveness and safety of endothelin-receptor antagonist (ERA) in the patients with hypertension. Searches of the PubMed, EMBASE, and CENTRAL databases were conducted to include all the randomized control trials (RCTs). Eighteen trials including 4898 patients were used in the meta-analysis, of which nine were classified as low risk of bias and the other nine as unclear risk of bias. There was no statistically significant difference in all-cause mortality between ERA and placebo groups [6 trials, fixed effects model, RR 1.53 (0.89–2.62); random effects model, RR 1.45 (0.84–2.52)]. ERA significantly reduced 24-h ambulatory blood pressure and sitting blood pressure in patients with hypertension [5 trials, 24-h SBP: WMD −7.65 (−8.95 to −6.36), 24-h DBP: WMD −5.92 (−7.50 to −4.33); 18 trials, SBP: WMD −6.12 (−7.87 to −4.36), DBP: WMD −3.81 (−4.82 to −2.80)]. However, ERA had more adverse events [within 24 h: 3 trials, RR 1.16 (0.82–1.65); after 24 h, 13 trials, RR 1.21 (1.08–1.36)] and severe adverse events than placebo controls [SAE: 9 trials, RR 1.34 (1.13–1.60)]. In addition, there is a potential need for further RCTs that focus on the use of ERA in patients with hypertension.

查看原文本刊更多论文

内皮素受体拮抗剂可以降低高血压患者的血压:荟萃分析

摘要本荟萃分析的目的是评估内皮素受体拮抗剂（ERA）在高血压患者中的有效性和安全性。检索PubMed、EMBASE和CENTRAL数据库，包括所有随机对照试验（RCT）。荟萃分析中使用了包括4898名患者在内的18项试验，其中9项被归类为低偏倚风险，另外9项被分类为不明确偏倚风险。ERA和安慰剂组之间的全因死亡率没有统计学上的显著差异[6项试验，固定效应模型，RR 1.53（0.89-2.62）；随机效应模型，RR1.45（0.84-2.52）]。ERA显著降低了高血压患者的24小时动态血压和坐位血压[5个试验，24小时SBP:WMD−7.65（−8.95至−6.36），24小时DBP:WMC−5.92（−7.50至−4.33）；18项试验，SBP:WMD−6.12（−7.87至−4.36），DBP:WMC−3.81（−4.82至−2.80）]。然而，ERA的不良事件更多[在24 h： 3个试验，RR 1.16（0.82-1.65）；24之后 h、 13项试验，RR 1.21（1.08-1.36）]和严重不良事件[SEA:9项试验，RR1.34（1.13-1.60）]。此外，还可能需要进一步的随机对照试验，重点关注ERA在高血压患者中的使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Pressure 医学-外周血管病

CiteScore

3.00

自引率

5.60%

发文量

审稿时长

6-12 weeks

期刊介绍： For outstanding coverage of the latest advances in hypertension research, turn to Blood Pressure, a primary source for authoritative and timely information on all aspects of hypertension research and management. Features include: • Physiology and pathophysiology of blood pressure regulation • Primary and secondary hypertension • Cerebrovascular and cardiovascular complications of hypertension • Detection, treatment and follow-up of hypertension • Non pharmacological and pharmacological management • Large outcome trials in hypertension.